propafenone has been researched along with Sclerosis, Systemic in 1 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, BE | 1 |
| Jiang, X | 1 |
| Zhang, Q | 1 |
| Liang, Q | 1 |
| Qiu, ZL | 1 |
| Sun, XB | 1 |
| Yang, JJ | 1 |
| Chen, S | 1 |
| Yi, C | 1 |
| Chai, X | 1 |
| Liu, M | 1 |
| Yu, LF | 1 |
| Lu, W | 1 |
| Zhang, HK | 1 |
1 other study available for propafenone and Sclerosis, Systemic
| Article | Year |
|---|---|
From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis.
Topics: Designer Drugs; Drug Discovery; Humans; Receptor, Cannabinoid, CB2; Scleroderma, Systemic; Structure | 2021 |